TransCode Therapeutics (RNAZ) Q2 2026 earnings summary

Executive summary

• Focused on immuno-oncology and targeted cancer therapies, with lead candidate TTX-MC138 advancing into Phase 2a clinical trials for colorectal cancer and a pipeline including Seviprotimut-L and other RNA-based therapeutics.

• Completed acquisition of Polynoma, adding Seviprotimut-L, a Phase III-ready melanoma vaccine, and entered a licensing agreement for a preclinical oncolytic virus program.

• Initiated collaborations with Quantum Leap and MD Anderson for clinical trials and amended strategic partnerships to focus on core programs.

Financial highlights

• Net loss for the six months ended June 30, 2026, was $24.5 million, compared to $16.4 million for the same period in 2025, driven by increased R&D and G&A expenses and a one-time $10.4 million non-cash R&D charge for the Unleash license.

• Cash as of June 30, 2026, was $8.4 million, with $1.0 million raised from a convertible note in the period; additional $4.75 million received in July 2026 from a second convertible note.

• Accumulated deficit reached $122.4 million as of June 30, 2026.

Outlook and guidance

• Cash on hand and recent financing expected to fund operations through year-end 2026; substantial additional capital will be required to continue development beyond that point.

• Ongoing focus on advancing TTX-MC138 in clinical trials and evaluating further development of Seviprotimut-L, contingent on funding.